RxDoctor Payments Data

Narayana Pula, MD

General Practice · Elkton, MDNPI 1801003488

Payments from drug & device makers

$860in general payments, 2019–2025

Across 54 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$109
  • AstraZeneca$90
  • Merck$81
  • Pfizer$77
  • Johnson & Johnson$67
  • Lilly USA, LLC$59
  • plus $376 from 12 others

What the payments were for

  • Food & beverage$860100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$860 in reported general payments places this provider in the 75th percentile of 1,843 general practice providers in Maryland.

See all general practice providers in Maryland

Medicare billing

Part B allowed, 2024
$117,089
Medicare patients
440
Services billed
1,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin57$84,762
OzempicSemaglutide55$84,060
TrulicityDulaglutide15$33,305
JanuviaSitagliptin Phosphate25$20,981
EliquisApixaban12$19,635
FarxigaDapagliflozin Propanediol18$18,186
XareltoRivaroxaban19$16,953
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,792
Breo ElliptaFluticasone/Vilanterol34$15,351
LinzessLinaclotide11$10,048
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$8,479
Atorvastatin Calcium511$6,200
Metoprolol Succinate255$3,713
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$3,532
Rosuvastatin Calcium126$3,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$58$84,76257 claims
Novo NordiskOzempic$109$84,06055 claims
Lilly USA, LLCTrulicity$59$33,30515 claims
MerckJanuvia$81$20,98125 claims
PfizerEliquis$77$19,63512 claims
AstraZenecaFarxiga$90$18,18618 claims
Johnson & JohnsonXarelto$67$16,95319 claims
AbbVieLinzess$25$10,04811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,843 general practice providers in Maryland.

Other general practice in Elkton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →